- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARCTIC BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 09:39 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Notice of Extraordinary General Meeting on 11 November 2025 | 2 | Cision News | ||
| 28.08. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Stable development with upside potential | 6 | Cision News | ||
| 21.08. | Arctic Bioscience AS: Arctic Bioscience - Invitation to presentation of half year 2025 results | 1 | Oslo Børs | ||
| 18.08. | Arctic Bioscience AS: Arctic Bioscience - Achieves significant vision improvement in Clinical Glaucoma Study | - | Oslo Børs | ||
| 12.08. | Arctic Bioscience AS: Arctic Bioscience launches new skin care product - Romega Skin Refine | - | Oslo Børs | ||
| 01.07. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - 12-month data confirm potential for HRO350 in mild-to-moderate psoriasis | 5 | Cision News | ||
| 26.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Minutes of the Annual General Meeting | 2 | Cision News | ||
| 15.05. | Arctic Bioscience AS: Arctic Bioscience - Q1 2025 Operational update - Growth-platform established | 1 | Oslo Børs | ||
| 12.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Share capital increase registered | 2 | Cision News | ||
| 12.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Notice of Annual General Meeting on 26 May 2025 | 2 | Cision News | ||
| 08.05. | Arctic Bioscience AS: Arctic Bioscience - Board approval of share capital increase related to conversion of debt | - | Oslo Børs | ||
| 07.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Annual report 2024 | 1 | Cision News |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,91 | -0,09 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,290 | +0,50 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| QIAGEN | 41,140 | -1,72 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,010 | +27,34 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| 89BIO | 14,835 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,520 | +2,04 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 199,36 | +6,71 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,320 | +0,67 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,970 | -2,52 % | 4D Molecular Therapeutics stock maintains Outperform rating at RBC Capital | ||
| EVOTEC | 7,074 | -0,70 % | Aktien Frankfurt: Solide Zahlen aus den USA schieben Kurse an | FRANKFURT (dpa-AFX) - Überwiegend robuste Quartalsbilanzen und Prognosen von US-Unternehmen haben dem deutschen Aktienmarkt am Dienstag etwas Anschub verliehen. Der Leitindex Dax, der sich bis zum... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,910 | -6,04 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| INTELLIA THERAPEUTICS | 11,975 | -3,85 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| JANUX THERAPEUTICS | 29,760 | +8,77 % | Janux Therapeutics gains amid renewed takevover speculation | ||
| ADMA BIOLOGICS | 15,600 | -0,03 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| BIONTECH | 90,30 | -0,82 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen |
ARCTIC BIOSCIENCE AS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCTIC BIOSCIENCE AS finden Sie auf Wallstreet Online.